| Line Item | 2025-02-28 | Y/Y |
|---|---|---|
| Revenue | $10.9M | +7017.0% |
| R&D Expense | $6.9M | -39.7% |
| SG&A Expense | $9.2M | -7.6% |
| Operating Income | -$15.1M | +28.6% |
| Income Tax | $0 | — |
| Net Income | -$15.1M | +28.6% |
| EPS (Diluted) | -$0.32 | +27.3% |
| Line Item | 2025-02-28 | Y/Y |
|---|---|---|
| Cash & Equivalents | $13.0M | +86.4% |
| Accounts Receivable | $639K | +82.1% |
| Inventory | $82K | -19.6% |
| Current Assets | $13.9M | +73.4% |
| Total Assets | $18.6M | -9.6% |
| Current Liabilities | $4.0M | +63.5% |
| Long-term Debt | $3.2M | -8.2% |
| Line Item | 2025-02-28 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$2.1M | +88.2% |
| Capital Expenditures | $0 | -100.0% |
| Investing Cash Flow | -$2.0M | +63.9% |
| Financing Cash Flow | $10.3M | — |
| Free Cash Flow | -$2.1M | +90.9% |
| Total Liabilities |
| $18.2M |
| +184.1% |
| Stockholders' Equity | $367K | -97.4% |